Alcon Inc. — Medical Instruments & Supplies. Scored on the same transparent 7-signal model behind the daily rankings.
★
ALC
Alcon Inc. · Medical Instruments & Supplies
FCF$2.1bB
Rev+10.5%B
D/E0.24B
P/E40.2xC+
PEG1.54C+
72.2Score
$67.95$33.1B
1Y Target$89.01Analyst consensus · 16 analysts
5Y Target$130.32Compound horizon
10Y Target$193.33Long-dated conviction
FCF$2.1bTTMB
FCF $2.1b — solid, comfortably covers operations and capital return
Rev+10.5%TTM YoYB
Revenue +10.5% — at or above S&P median
D/E0.24B
D/E 0.24 — near the Healthcare debt median (≈60th pctile)
P/E40.2xC+
P/E 40.2 — above the Healthcare median (≈75th pctile)
PEG1.54C+
PEG 1.54 — modest premium; above fair value
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 72.2
Quality0.87
Growth0.71
Value0.60
Why this score
Durable high returns
Entry · Margin of safety
52-week rangeNear 52-week low
27% off the 12-month high
vs DCF fair value36% belowest. fair value ~$105
Quality signals · context only
Gross profitability55% · Agross profit ÷ total assets (Novy-Marx)
ROIC25.6% · Areturn on invested capital — not score-weighted
Why now
Medical Instruments & Supplies · market cap $33.1b. Down 27% from 52-week high of $92.55 — deep drawdown territory. Revenue growing +10%, comfortably above the S&P median. 16 sell-side analysts rate this a Buy with a mean 1-yr target of $89.01 (implying +31% upside).
Moat
Net margin 31% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 30% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk
Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon
1-3 yr $89.01 (16-analyst consensus) — fundamentals + valuation re-rating. 5 yr $130.32 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $193.33 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · ALC
Trend
+6.2 over 14 daily scores
From 66.0 (Jun 22) → 72.2 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · ALC
$
%
%
Shares to buy
29
Position size
$1,971
3.9% of portfolio
Stop price
$50.96
25% below $67.95
$ at risk if stopped
$492.64
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Alcon Inc. (ALC): score, valuation & FAQ
Alcon Inc. (ALC) is a Medical Instruments & Supplies company that scores 72.2 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
On valuation, ALC sits about 36% below our discounted-cash-flow fair value (a margin of safety).
Is ALC a good stock to buy?
Bull Rankings scores ALC 72.2 out of 100 on its quality-growth model, which is a solid, above-average reading. A score is a quantitative screen of Alcon Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does ALC score 72.2 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). ALC grades middle-of-pack across the strip. Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is ALC overvalued or undervalued?
Based on $67.95, ALC sits about 36% below our discounted-cash-flow fair value (a margin of safety). It trades at a 40.2x× P/E (graded C+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in ALC?
Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.